There are 2949 resources available
440P - Phase III randomized trial comparing short-term infusion of oxaliplatin and capecitabine (Xelox30) with chronomodulated (Xelox30) in patients with advanced and/or metastatic colorectal cancer
Presenter: Mona Nafea
Session: E-Poster Display
Resources:
Abstract
441P - Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study
Presenter: Jobst von Einem
Session: E-Poster Display
Resources:
Abstract
442P - Camrelizumab combined with apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: One-arm exploratory clinical trial
Presenter: Li Xiao
Session: E-Poster Display
Resources:
Abstract
443P - First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study
Presenter: Claire Gallois
Session: E-Poster Display
Resources:
Abstract
444P - PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
Presenter: Jean Louis Legoux
Session: E-Poster Display
Resources:
Abstract
445P - Real-world evidence (RWE) on the clinical outcomes in 1st-line chemotherapy (CT) for fit and vulnerable patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Kentaro Yamazaki
Session: E-Poster Display
Resources:
Abstract
446P - Real-world data (RWD) survival analysis of first line (1L) metastatic colorectal cancer (mCRC) patients (pts) with BRAF V600 and non-V600, KRAS G12 and G13, and NRAS mutations
Presenter: Anda Gershon
Session: E-Poster Display
Resources:
Abstract
447P - Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study
Presenter: Eleonora Lai
Session: E-Poster Display
Resources:
Abstract
448P - Predictive factor of cardiotoxicity in fluoropyrimidine-treated colorectal cancer patients: Interim analysis of the prospective observational CHECKPOINT trial
Presenter: Giacomo Aimar
Session: E-Poster Display
Resources:
Abstract
449P - Randomized phase II study comparing pathological responses of resected colorectal cancer metastases (CRCM) after bevacizumab (BEV) with FOLFOX or FOLFIRI (BEV-ONCO trial)
Presenter: Pamela Baldin
Session: E-Poster Display
Resources:
Abstract